The “whole genome” TMV-based expression system, Geneware®, was used in the cGMP production of the plant-made pharmaceutical Q-Griffithsin and demonstrates stable expression for up to a two-year period. Virion and plasmid banks which contained viral cDNA and a Q-Griffithsin sequence were able to produce >200 g of Q-Griffithsin. Data assessing the quality and stability of the product banks were measured through functional assessments of visual symptomology and product expression.

中文翻译：

---

支持从基于 TMV 的病毒载体 cGMP 生产 Q-Griffithsin 的质粒和病毒库的稳定性。

“全基因组”基于 TMV 的表达系统 Geneware® 用于植物药物 Q-Griffithsin 的 cGMP 生产，并展示了长达两年的稳定表达。包含病毒 cDNA 和 Q-Griffithsin 序列的病毒粒子和质粒库能够产生 >200 g Q-Griffithsin。评估产品库质量和稳定性的数据是通过视觉症状和产品表达的功能评估来衡量的。